Axsome Therapeutics (AXSM) Given News Sentiment Rating of 0.52

Press coverage about Axsome Therapeutics (NASDAQ:AXSM) has been trending very positive on Tuesday, according to AlphaOne. The research group, a subsidiary of Accern, scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Axsome Therapeutics earned a news impact score of 0.52 on AlphaOne’s scale. AlphaOne also assigned news headlines about the company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news articles that may have impacted Alpha One’s rankings:

Insider Buying and Selling by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics (NASDAQ:AXSM) opened at 4.60 on Tuesday. Axsome Therapeutics has a 52 week low of $3.53 and a 52 week high of $9.11. The firm’s 50 day moving average price is $4.06 and its 200-day moving average price is $4.72. The firm’s market cap is $108.58 million.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, May 9th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by $0.01. On average, analysts forecast that Axsome Therapeutics will post ($1.41) EPS for the current year.

A number of research analysts recently weighed in on the company. Cantor Fitzgerald set a $13.00 target price on Axsome Therapeutics and gave the company a “buy” rating in a report on Wednesday, March 8th. Aegis restated a “buy” rating and set a $20.00 price objective on shares of Axsome Therapeutics in a research note on Tuesday. Zacks Investment Research upgraded Axsome Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a research note on Monday. Finally, BTIG Research began coverage on Axsome Therapeutics in a research note on Friday, May 19th. They set a “buy” rating and a $14.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $14.30.

COPYRIGHT VIOLATION WARNING: “Axsome Therapeutics (AXSM) Given News Sentiment Rating of 0.52” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/2654958/axsome-therapeutics-axsm-given-news-sentiment-rating-of-0-52.html.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:AXSM”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
Shares at Radius Jump as Bone Drug of Amgen Has Setback
Shares at Radius Jump as Bone Drug of Amgen Has Setback


© 2006-2017 Ticker Report. Google+.